Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Pharmacogenomic Test"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Medical review. 74:117-122
Introduction. The combinatorial pharmacogenomic test has shown the potential to predict antidepressant response, tolerability, selection, and dosage in the treatment of a major depressive disorder. A case of successful management of antidepressant th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d21795bb9d165e093bf6295b89878fb9
https://doi.org/10.2298/mpns2104117v
https://doi.org/10.2298/mpns2104117v
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Charles R. Conway, Boadie W. Dunlop, Matthew Macaluso, Paul Traxler, Anthony J. Rothschild, Michael E. Thase, Charles DeBattista, Sagar V. Parikh, James Li, Jennifer Logan, Lisa M. Brown, Sara L. Weisenbach, Olusola Ajilore, Richard C. Shelton, Bryan Dechairo, Brent P. Forester, Ipsit V. Vahia, John F. Greden
Publikováno v:
Focus (Am Psychiatr Publ)
Objective Evaluate the clinical utility of combinatorial pharmacogenomic testing for informing medication selection among older adults who have experienced antidepressant medication failure for major depressive disorder (MDD). Design Post hoc analysi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9929458983284477fbb8b4e8e6a16f17
https://doi.org/10.1016/j.jagp.2020.05.005
https://doi.org/10.1016/j.jagp.2020.05.005
Autor:
Krystal Brown, Lisa M. Brown, Kunbo Yu, Michael R. Jablonski, James Li, Holly Johnson, Talal Al Habbab, Oliver Vranjkovic, Bryan Dechairo
Publikováno v:
Pharmacogenomics. 21:559-569
Aim: To perform a meta-analysis of prospective, two-arm studies examining the clinical utility of using the combinatorial pharmacogenomic test, GeneSight Psychotropic, to inform treatment decisions for patients with major depressive disorder (MDD). P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a00b2b4bf6a5b79cd1bce003d36950ff
https://doi.org/10.2217/pgs-2019-0157
https://doi.org/10.2217/pgs-2019-0157
Publikováno v:
Journal of Personalized Medicine
Volume 11
Issue 11
Journal of Personalized Medicine, Vol 11, Iss 1112, p 1112 (2021)
Volume 11
Issue 11
Journal of Personalized Medicine, Vol 11, Iss 1112, p 1112 (2021)
(1) Background: Chronic pain is one of the most common reasons for individuals to seek medications. Historically, opioids have been the mainstay of chronic pain management. However, in some patient populations, opioids fail to demonstrate therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e51b0cecf47f2bbcb7ec799c31bc8977
https://pubmed.ncbi.nlm.nih.gov/34834463
https://pubmed.ncbi.nlm.nih.gov/34834463
Publikováno v:
ClinicoEconomics and Outcomes Research. 11:779-787
Objective To estimate Canadian pharmacy cost savings associated with psychiatric medication prescribing that is guided by combinatorial pharmacogenomic testing in patients switching or augmenting their psychiatric medication. Methods Pharmacy claims
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2c9cba944642786d5770514ee0271a6
https://doi.org/10.2147/ceor.s224277
https://doi.org/10.2147/ceor.s224277
Publikováno v:
J Am Pharm Assoc (2003)
Objective To explore the implications of direct-to-consumer pharmacogenomic testing for community pharmacy practice. Summary In October 2018, the U.S. Food and Drug Administration provided approval for direct-to-consumer genetic testing company, 23an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7fa4e62c6feca77067074b4551c3d78
https://doi.org/10.1016/j.japh.2019.06.008
https://doi.org/10.1016/j.japh.2019.06.008
Autor:
Susanne B. Haga
Publikováno v:
Personalized medicine. 17(6)
The field of pharmacogenetic testing was hailed as one of the early successful clinical applications arising from the personalized (or precision) medicine revolution. Substantial progress has been made to identify genes and genetic variants involved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6287ac71bf1561d94f6f714f39fd9708
https://pubmed.ncbi.nlm.nih.gov/33026284
https://pubmed.ncbi.nlm.nih.gov/33026284
Autor:
Boadie W. Dunlop, John F. Greden, Charles DeBattista, Rebecca A. Law, Krystal Brown, Anthony J. Rothschild, Michael R. Jablonski, Michael E. Thase, Alexander Gutin, Brent P. Forester, Sagar V. Parikh, Richard C. Shelton, Charles R. Conway, Daniel T. Hain, David A. Lewis, Matthew Macaluso
Publikováno v:
Psychiatry research. 296
We evaluated the clinical validity of a combinatorial pharmacogenomic test and single-gene Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines against patient outcomes and medication blood levels to assess their ability to inform pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38c56eeb8d7431db0abc112f015b81d9
https://pubmed.ncbi.nlm.nih.gov/33360967
https://pubmed.ncbi.nlm.nih.gov/33360967